FDA pushes decision on Belite’s eye disease pill back to May

Close-up of human eye
Belite holds the FDA’s breakthrough therapy, fast track and rare pediatric disease designations for STGD1. (iStock / Getty Images Plus)

The FDA is taking a little extra time to review Belite Bio’s application for its treatment for a rare genetic eye condition, pushing the expected action date back by three months into May next year.

The agency told Belite that the extension to May 12 from the original PDUFA date of Feb. 12 would provide additional time to review the company’s new drug application for tinlarebant. The oral small-molecule drug candidate reduces vitamin A-related toxins that cause retinal disease in patients with Stargardt disease type 1 (STGD1).

Tinlarebant passed its phase 3 test in December 2025 with a 35.7% reduction in lesion growth rate versus placebo, meeting the late-stage trial’s primary endpoint. If approved, the drug would be the first for STGD1 in the U.S., although a gene therapy from Ocugen is also in mid- to late-stage development with data expected in the first half of 2027.

Belite holds the FDA’s breakthrough therapy, fast track and rare pediatric disease designations for STGD1.

The regulatory green light would also be a promising sign for the company’s tinlarebant plans in the more common retinal eye diseases geographic atrophy and age-related macular degeneration. In geographic atrophy, where Belite is running a phase 3 trial, tinlarebant would enter a market that already has two drugs approved in the U.S. in the form of Astellas’ Izervay and Apellis Pharmaceuticals’ Syfovre. Both approved therapies are intravitreal injections compared with Belite’s oral option.

Although tinlarebant is being investigated for diseases of the eye, its method of action starts in the liver, where vitamin A-based retinol is created. The drug candidate targets the transport protein that carries retinol to the eye.

Belite’s preclinical pipeline includes the anti-RBP4 oral therapy LBS-009, which targets non-alcoholic fatty liver disease and type 2 diabetes.